industryterm:healthcare delivery

The normalization of deviance

Social normalization of deviance means that people within the organization become so much accustomed to a deviation that they don’t consider it as deviant, despite the fact that they far exceed their own rules for the elementary safety

—Diane Vaughan, 1996

The normalization of deviance in healthcare delivery, by John Banja
▻https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2821100

In other words, mistakes such as failing to check or record a lab finding, ordering the wrong drug, or entering a lab finding in the wrong patient’s chart are usually not enough to guarantee an occurrence of harm. The recipe for disaster additionally requires these errors, lapses, or mistakes to go unattended, unappreciated, or unresolved for an extended period of time.

In software Engineering, by Dan Luu
►https://danluu.com/wat

In engineering (and eventually life in general), by Foone Turing
▻https://foone.wordpress.com/2019/02/14/normalization-of-deviance

#normalizationOfDeviance #sociology #risk

Paul Farmer · Diary: Ebola
►http://www.lrb.co.uk/v36/n20/paul-farmer/diary

Anyone whose metrics or proof are judged wanting is likely to receive a cool reception, even though the #Ebola crisis should serve as an object lesson and rebuke to those who tolerate anaemic state funding of, or even cutbacks in, public health and healthcare delivery. Without staff, stuff, space and systems, nothing can be done.

If such things were thin on the ground in Monrovia and Freetown, they were all but absent in rural regions. (...)

Ebola is more a symptom of a weak healthcare system than anything else. But until this diagnosis is agreed on, there’s plenty of room for other, more exotic explanations.

#métriques #ebola #santé

#Cancer Drug Innovation Surges As Cost Growth Moderates - FiercePharmaMarketing
▻http://www.fiercepharmamarketing.com/press-releases/ims-health-study-cancer-drug-innovation-surges-cost-growth-mo

In the U.S. market, which contributes 41 percent of total oncology drug sales, changes in the structure of healthcare delivery are impacting cancer treatment site of care, reimbursement and patient out-of-pocket costs. Physician practices are becoming larger, and healthcare organizations that care for underserved populations and are covered by the 340B Drug Discount Program have expanded their oncology presence, as have Accountable Care Organizations. This is resulting in a shift in patient care from physician offices to hospital outpatient facilities. (...) These higher costs are also associated with higher patient out-of-pocket costs depending on insurance plans and benefit designs, and can trigger reduced levels of therapeutic persistence by patients and higher overall cost of care.

via @jamielove